Evidence map›Paper›PMID 38658485›Full record

ArticleAdvances in therapy2024

Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn's Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study.

Andres Yarur, Gerassimos J Mantzaris, Song Wang, Shashi Adsul, Pravin Kamble, Erin Cook, Gautam Sajeev, Annie Guerin, Brian Bressler

2 registry-linked trialsOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03710486 completednot on this map

Vedolizumab and Anti-TNFs Outcomes in Real-World Biologic Ulcerative Colitis and Crohn's Disease Patients

TypeobservationalSponsorTakedaRan2019 to 2022Enrolled409ConditionsColitis, Ulcerative, Crohn Disease
NCT07273760 completednot on this map

A Prospective and Observational Study for Effectiveness and Safety Evaluation of VedAryo® (Vedolizumab) in Patients With Inflammatory Bowel Disease

Typeobservational_patient_registrySponsorAryoGen Pharmed Co.Ran2023 to 2025Enrolled150ConditionsUlcerative Colitis (UC), Crohn Disease (CD), Inflammatory Bowel Disease (IBD)ArmsVedolizumab
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Diagnostics (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Andres YarurCedars Sinai Medical Center, 8700 Beverly Blvd. Ste AC1128, Los Angeles, CA, USA. ajyarur@gmail.com.ORCID 0000-0003-2293-5555
Gerassimos J MantzarisEvangelismos Hospital, Athens, Greece.
Song WangTakeda Pharmaceuticals International Inc, Cambridge, MA, USA.
Shashi AdsulTakeda Pharmaceuticals International Inc, Cambridge, MA, USA.
Pravin KambleTakeda Pharmaceuticals International Inc, Cambridge, MA, USA.
Erin CookAnalysis Group, Boston, MA, USA.
Gautam SajeevAnalysis Group, Boston, MA, USA.
Annie GuerinAnalysis Group, Montreal, QC, Canada.
Brian BresslerSt. Paul's Hospital, Vancouver, BC, Canada.
Takeda (United States) · USAnalysis Group (United States) · USCedars-Sinai Medical Center · USEvangelismos Hospital · GRSt. Paul's Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis analysis evaluated the relative performance of vedolizumab and anti-tumor necrosis factor alpha (anti-TNFα) agents in subpopulations of biologic therapy-naive patients with Crohn's disease (CD) and assessed whether patients in whom vedolizumab would have a larger treatment effect vs anti-TNFα agents could be identified.

methodsData were from EVOLVE, a real-world, multicountry, retrospective cohort study of patients with inflammatory bowel disease who initiated first-line biologic treatment with vedolizumab (n = 195) or anti-TNFα agents (n = 245). Prediction models for time to clinical remission were developed in vedolizumab- and anti-TNFα-treated patients and used to estimate effect scores, a metric of predicted comparative efficacy, for each patient. Patients were ranked by effect scores and potential subpopulations were investigated. Simplified rules to identify these subpopulations were also developed using classification tree analysis.

resultsAmong all patients, median time to clinical remission was 7.8 months (vedolizumab) and 11.1 months (anti-TNFα) (P < 0.05). Among patients in the top 40% of the effect score distribution, the median time to clinical remission was 4.8 months (vedolizumab) vs 18.1 months (anti-TNFα) (adjusted hazard ratio 2.0, 95% confidence interval 1.3-2.9). A simplified rule for identifying a subpopulation more likely to benefit from vedolizumab was based on having an ongoing CD exacerbation, no prior emergency visits, and non-stricturing disease.

conclusionsSubpopulations of biologic-naive patients with CD in whom vedolizumab appeared to have a larger effect relative to anti-TNFα agents for the outcome of clinical remission were identified. Validation of the identified subpopulations and simplified rules are warranted to confirm these findings. CLINICALTRIALS: GOV IDENTIFIER: NCT03710486. Graphical Abstract available for this article.

Indexed as

Antibodies, Monoclonal, HumanizedCrohn DiseaseGastrointestinal AgentsTumor Necrosis Factor-alphaAdultFemaleHumansMaleMiddle AgedRemission InductionRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedGastrointestinal AgentsTumor Necrosis Factor-alphavedolizumabCrohn’s diseaseTreatment responseVedolizumab

Identifiers

PMID38658485
PMCPMC11133170
OpenAlexW4395068084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.